Quick Answer
Yes. An adult may meet the diagnostic criteria for PMOS even when an ultrasound does not show polycystic ovarian morphology. Providers also consider ovulatory dysfunction and clinical or laboratory signs of excess androgen activity after ruling out other possible causes. Symptoms alone do not confirm PMOS, but a normal ultrasound does not necessarily rule it out.
What Are “Polycystic Ovaries”?
The recent name change of polycystic ovary syndrome (PCOS) to polyendocrine metabolic syndrome (PMOS), highlighted a previous emphasis on ovarian cysts as the defining feature of the condition rather than metabolic syndrome.
For clarity, the rest of this article refers to the condition as PMOS. The name change does not mean that every person with PMOS has metabolic syndrome. Instead, it reflects the broader endocrine, metabolic, reproductive, and ovarian features that healthcare providers may consider.
The ultrasound finding associated with PMOS usually does not mean abnormal or pathological ovarian cysts. Clinicians assess polycystic ovarian morphology, which describes an increased number of small follicles or increased ovarian volume.
Follicles are fluid-filled structures that contain developing eggs. They are different from the ovarian cysts people may associate with pain, rupture, or another ovarian condition.
This distinction helps explain why ovarian appearance alone does not define PMOS.
Does PMOS Require Ovarian Cysts?
No. Ovarian cysts aren’t required for an adult PMOS diagnosis.
After ruling out other possible causes, healthcare providers generally look for at least two of three features:
- Ovulatory dysfunction, which may appear as irregular, infrequent, or absent menstrual cycles
- Clinical or biochemical hyperandrogenism, meaning physical signs or laboratory evidence of increased androgen activity
- Polycystic ovarian morphology, identified through ultrasound or, in some adults, serum anti-Müllerian hormone testing
The current international guideline allows providers to use serum AMH as an alternative to ultrasound when evaluating ovarian morphology in adults. However, providers should not use AMH alone to diagnose PMOS.
An adult may therefore meet the diagnostic criteria through ovulatory dysfunction and signs of increased androgen activity. An ultrasound does not have to show polycystic ovarian morphology.
Does a Normal Ultrasound Rule Out PMOS?
Not necessarily.
An ultrasound provides information about ovarian appearance, but it does not evaluate every feature associated with PMOS. An adult with irregular menstrual cycles and clinical or biochemical hyperandrogenism may not need ultrasound or AMH as part of the diagnostic process.
A normal ultrasound also does not explain irregular periods, unwanted hair growth, persistent acne, or changes in ovulation. Those symptoms may have several possible causes. A provider should evaluate them within the person’s complete medical history.
A healthcare provider should interpret the ultrasound result within the patient’s broader clinical picture. PMOS evaluation may also involve a symptom history, physical examination, laboratory testing, medication review, and testing to exclude other possible conditions.
Provider Note: For adults with irregular menstrual cycles and hyperandrogenism, the international diagnostic algorithm may not require ultrasound or AMH after providers rule out other possible causes. Adolescent diagnostic criteria differ, and ultrasound and AMH are not recommended for diagnosing PMOS in adolescents.
Symptoms Worth Discussing With a Healthcare Provider
PMOS may look different from one patient to another. Some people have noticeable menstrual changes, while others first seek care because of skin, hair, or fertility concerns.
Changes worth discussing with a provider may include:
- Irregular, infrequent, or absent menstrual periods
- Persistent or severe acne
- New or increasing coarse hair growth on the face, abdomen, or body
- Heavy or prolonged menstrual bleeding
- Difficulty tracking ovulation
- Fertility concerns
These symptoms do not confirm PMOS by themselves. For example, acne and heavy bleeding may have several possible causes.
The timing and combination of symptoms matter. Keeping a simple record may help a provider identify patterns. It could include cycle dates, symptom changes, laboratory results, and ultrasound findings.
What the PMOS Name Change Clarifies
PMOS is not a newly discovered condition. It is the updated name for PCOS.
The change helps clarify that:
- Pathological ovarian cysts do not define the condition.
- A particular ovarian appearance does not have to be present in every adult diagnosis.
- Hormonal, metabolic, reproductive, and ovarian features may all be relevant.
- The condition may present differently from one patient to another.
The names PMOS and PCOS will appear together during the transition period. The next international guideline update is expected to expand use of the new name.
The Lancet global consensus described the old name as inaccurate. It could imply pathological ovarian cysts while obscuring the condition’s endocrine and metabolic features. The naming process also considered patient experience, communication, stigma, cultural relevance, and scientific accuracy.
When a Prescribed Hormone Option Requires More Flexibility
A licensed healthcare provider should evaluate symptoms and determine whether a patient meets the diagnostic criteria for PMOS.
A patient’s prescription needs may influence the medication strength, dosage form, ingredients, and product availability. If an available commercial medication does not meet those needs, a prescriber may consider a patient-specific compounded preparation.
Central Ohio Compounding Pharmacy prepares prescribed hormone-related medications in the strengths and dosage forms requested by prescribers. We also offer hormone test kits that may help patients prepare questions for their healthcare providers. These tests do not diagnose PMOS.
COCPRx has locations in Worthington and the Arena District. We serve patients and practitioners throughout Ohio and offer statewide prescription shipping.
Have questions about irregular cycles, acne, unwanted hair growth, fertility concerns, or other hormone-related changes? Schedule a private consultation with Lucy, our hormone pharmacist.
Next in the PMOS Series
Why Metabolic Health Matters in PMOS
The next article will explain why “metabolic” is part of the PMOS name. It will also explore how insulin resistance and other metabolic factors may relate to the condition.
Frequently Asked Questions about PCOS/PMOS
Can you have PCOS without ovarian cysts?
Yes. An adult may meet the diagnostic criteria for PMOS without polycystic ovarian morphology appearing on an ultrasound. Providers consider ovulatory dysfunction, hyperandrogenism, and ovarian morphology after excluding other possible causes.
Does a normal ultrasound rule out PMOS?
No. A normal ultrasound does not automatically rule out PMOS. When ovulatory dysfunction and clinical or biochemical hyperandrogenism are both present, ultrasound or AMH may not be required for an adult diagnosis.
Are ovarian cysts and polycystic ovarian morphology the same?
No. Polycystic ovarian morphology refers to increased small ovarian follicles or increased ovarian volume. These findings are different from the pathological ovarian cysts commonly associated with the word “cyst.”
References
- Endocrine Society. (2026, May 12). Polyendocrine metabolic ovarian syndrome: New name to improve diagnosis and care of condition affecting 170 million women worldwide. Link
- Teede, H. J., Khomami, M. B., Morman, R., Laven, J. S. E., Joham, A. E., Costello, M. F., Patil, M., Rees, D. A., Berry, L., Cree, M. G., Zhao, H., Norman, R. J., Dokras, A., Piltonen, T., & Global Name Change Consortium. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: A multistep global consensus process. The Lancet, 407(10545), 2329–2339. Link
- Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., Joham, A. E., & International PCOS Network. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 108(10), 2447–2469. Link